MX2014015558A - Analogos de glucagon que exhiben actividad del receptor gip. - Google Patents

Analogos de glucagon que exhiben actividad del receptor gip.

Info

Publication number
MX2014015558A
MX2014015558A MX2014015558A MX2014015558A MX2014015558A MX 2014015558 A MX2014015558 A MX 2014015558A MX 2014015558 A MX2014015558 A MX 2014015558A MX 2014015558 A MX2014015558 A MX 2014015558A MX 2014015558 A MX2014015558 A MX 2014015558A
Authority
MX
Mexico
Prior art keywords
gip receptor
receptor activity
glucagon analogs
analogs exhibiting
exhibiting gip
Prior art date
Application number
MX2014015558A
Other languages
English (en)
Inventor
Richard D Dimarchi
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2014015558A publication Critical patent/MX2014015558A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Se proporcionan en la presente, análogos de glucagón que exhiben potente actividad en el receptor GIP, 'y, como tales se contemplan para el uso en el tratamiento de la diabetes y obesidad. En modalidades ejemplares, el análogo de glucagón de las presentes descripciones exhibe una EC50 en el receptor GIP que está dentro del intervalo nanomolar o picomolar.
MX2014015558A 2012-06-21 2013-06-18 Analogos de glucagon que exhiben actividad del receptor gip. MX2014015558A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662868P 2012-06-21 2012-06-21
US201261716878P 2012-10-22 2012-10-22
PCT/US2013/046228 WO2013192129A1 (en) 2012-06-21 2013-06-18 Glucagon analogs exhibiting gip receptor activity

Publications (1)

Publication Number Publication Date
MX2014015558A true MX2014015558A (es) 2015-03-05

Family

ID=48699335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015558A MX2014015558A (es) 2012-06-21 2013-06-18 Analogos de glucagon que exhiben actividad del receptor gip.

Country Status (13)

Country Link
US (1) US9340600B2 (es)
EP (1) EP2864351B1 (es)
JP (1) JP6311708B2 (es)
KR (1) KR20150023013A (es)
CN (1) CN104583232B (es)
AR (1) AR091477A1 (es)
CA (1) CA2877358A1 (es)
ES (1) ES2602486T3 (es)
HK (1) HK1209764A1 (es)
MX (1) MX2014015558A (es)
RU (1) RU2015101697A (es)
TW (1) TWI599575B (es)
WO (1) WO2013192129A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체-활성 글루카곤 화합물
PT2718318T (pt) 2011-06-10 2018-11-09 Hanmi Science Co Ltd Derivados de oxintomodulina inovadores e composição farmacêutica para tratar a obesidade compreendendo os mesmos
PE20181268A1 (es) 2011-06-17 2018-08-03 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y el uso del mismo
MX347703B (es) 2011-06-22 2017-05-09 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1.
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2916819T (pt) 2012-11-06 2019-10-28 Hanmi Pharm Ind Co Ltd Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina.
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
HUE038748T2 (hu) 2012-12-21 2018-11-28 Sanofi Sa Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták
MA38472B1 (fr) 2013-05-28 2018-09-28 Takeda Pharmaceuticals Co Composé peptidique
AR098614A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
KR20160114082A (ko) 2014-02-18 2016-10-04 노보 노르디스크 에이/에스 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
ES2822994T3 (es) * 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
TW201639878A (zh) 2014-12-30 2016-11-16 韓美藥品股份有限公司 具有改善之安定性的升糖素衍生物
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AU2016287209B2 (en) 2015-06-30 2023-03-02 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
PT3398961T (pt) * 2015-12-31 2022-09-05 Hanmi Pharm Ind Co Ltd Ativador triplo ativando recetor glucagon, glp-1 e gip
CN109477094B (zh) 2016-05-24 2022-04-26 武田药品工业株式会社 肽化合物
NZ750267A (en) 2016-06-29 2023-12-22 Hanmi Pharm Ind Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類glp1/升糖素/gip受體促效劑之新化合物
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
GB201620611D0 (en) * 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EP3774838B1 (en) 2018-04-10 2022-08-10 Sanofi-Aventis Deutschland GmbH Lixisenatide synthesis with capping
BR112020020652A2 (pt) 2018-04-10 2021-03-02 Sanofi-Aventis Deutschland Gmbh método para clivagem de peptídeos ligados à fase sólida a partir da fase sólida
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含glp-1/升糖素/gip三重受體促效劑、連接子及透明質酸之接合物
CN111171134B (zh) * 2018-11-12 2023-08-15 天津药物研究院有限公司 胰高血糖素衍生肽及其用途
JP2022509568A (ja) * 2018-12-03 2022-01-20 アンタグ セラピューティクス エーピーエス 修飾されたgipペプチド類似体
CN110128526B (zh) * 2019-05-30 2021-07-23 江苏诺泰澳赛诺生物制药股份有限公司 长效化艾塞那肽衍生物及其盐与制备方法和用途
TW202114728A (zh) * 2019-06-28 2021-04-16 南韓商韓美藥品股份有限公司 三重升糖素/glp-1/gip受體促效劑或其接合物用於肝臟疾病之治療用途
US20230183310A1 (en) * 2020-02-24 2023-06-15 Shenzhen Turier Biotech Co., Ltd. Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications
EP4183407A1 (en) * 2020-07-15 2023-05-24 Hanmi Pharm. Co., Ltd. Therapeutic use of glucagon derivative or conjugate thereof for liver disease
CN116209475A (zh) * 2020-07-17 2023-06-02 韩美药品株式会社 包括三重激动长效缀合物或三重激动剂的组合的治疗用途
TW202220700A (zh) * 2020-08-14 2022-06-01 南韓商韓美藥品股份有限公司 包含三重升糖素/glp-1/gip受體促效劑的長效接合物的醫藥組成物
WO2022079639A1 (en) * 2020-10-17 2022-04-21 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
EP4249505A1 (en) * 2020-12-23 2023-09-27 Zhejiang Doer Biologics Co., Ltd. Long-acting glucagon derivative
CN117120462A (zh) * 2021-01-22 2023-11-24 深圳市图微安创科技开发有限公司 多肽化合物在预防或治疗炎症性肠病及其相关的肠纤维化中的应用
KR20220140443A (ko) * 2021-04-09 2022-10-18 한미약품 주식회사 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물
CN117242087A (zh) * 2021-06-18 2023-12-15 北京拓界生物医药科技有限公司 胰高血糖素类似物及其医药用途
KR20230095665A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 약물 및 이의 용도
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4275152A (en) 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
JPH04504416A (ja) 1989-02-17 1992-08-06 コセルコ・ミモトープス・ピィ・ティ・ワイ.エル・ティ・ディ. ペプチドの使用方法と合成方法
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
CA2024855C (en) 1990-09-07 1997-12-09 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Process and intermediates for producing glucagon
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Gip様活性を有するポリペプチド誘導体及びその用途
US5510459A (en) 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
AU2263197A (en) 1996-02-06 1997-08-28 Eli Lilly And Company Diabetes therapy
KR100600457B1 (ko) 1996-06-05 2006-07-13 로셰 디아그노스틱스 게엠베하 엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
JP2001505872A (ja) 1996-09-09 2001-05-08 ジーランド ファーマシューティカルズ アクティーゼルスカブ α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
CN1296417A (zh) 1998-02-10 2001-05-23 卫福有限公司 控释制剂
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
WO2000020592A1 (en) 1998-10-07 2000-04-13 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
PT1171465E (pt) 1999-03-29 2004-12-31 Uutech Ltd Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
AU2001257278A1 (en) 2000-04-27 2001-11-07 Bionebraska, Inc. Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
AU2001269833A1 (en) 2000-06-14 2001-12-24 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
KR100847615B1 (ko) 2000-06-16 2008-07-21 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드-1 유사체
EP1305338A2 (en) 2000-08-02 2003-05-02 Theratechnologies Inc. Modified peptides with increased potency
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
EP1324779B1 (en) 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1572885A2 (en) 2001-08-08 2005-09-14 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
BR0213377A (pt) 2001-10-18 2006-05-23 Bristol Myers Squibb Co mìmico de peptìdeo semelhante ao glucagon 1 humano e seu uso no tratamento de diabetes e condições relacionadas
CA2463803A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
EP1461069A2 (en) 2001-12-29 2004-09-29 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2003103572A2 (en) 2002-06-04 2003-12-18 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
JP2006502100A (ja) 2002-06-11 2006-01-19 エーザイ株式会社 細胞の異常消失に関わる障害の治療のための、および/または、肥満の治療のためのgip活性を有する化合物の使用
BR0311843A (pt) 2002-06-15 2005-03-15 Enteromed Inc Métodos para prevenir, inibir, tratar ou reduzir esteatose hepática não- alcoólica em um animal e para prevenir o desenvolvimento e/ou a reversão do processo de nafld em um animal
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
PL1605897T3 (pl) 2003-03-19 2012-12-31 Lilly Co Eli Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7259234B2 (en) 2003-05-15 2007-08-21 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー/エス 安定化された薬学的ペプチド組成物
CA2527743A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
PL1641823T3 (pl) 2003-06-12 2012-02-29 Lilly Co Eli Białka fuzyjne analogu GLP-1
US20050124550A1 (en) 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
SI2932981T1 (sl) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
US7364875B2 (en) 2003-10-30 2008-04-29 Cresent Innovations, Inc. Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
DE602004026113D1 (de) 2003-12-18 2010-04-29 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
EP2392595A1 (en) 2005-02-11 2011-12-07 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable properties
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
PL1881850T3 (pl) 2005-05-13 2011-03-31 Lilly Co Eli Pegylowane związki GLP-1
DK1891105T3 (da) * 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007028633A2 (en) 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
AU2006289259A1 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
ES2507098T3 (es) 2005-11-07 2014-10-14 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
EP1991574B1 (en) 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
JP5412273B2 (ja) 2006-03-21 2014-02-12 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー ペプチド−ぺプチダーゼ阻害剤及びその使用
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008022015A2 (en) 2006-08-11 2008-02-21 Trustees Of Tufts College Retro-inverso incretin analogues, and methods of use thereof
AU2007284365A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR101034888B1 (ko) 2007-04-19 2011-05-17 동아제약주식회사 지속제어 방출 양상을 갖는 당조절 펩타이드 함유 생분해성고분자 미립구 및 그 제조방법
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN101842386A (zh) 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
EP2650006A1 (en) 2007-09-07 2013-10-16 Ipsen Pharma S.A.S. Analogues of exendin-4 and exendin-3
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
WO2009034117A1 (en) 2007-09-11 2009-03-19 Novo Nordisk A/S Mixture comprising an amylin peptide and a protracted insulin
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
JP5771005B2 (ja) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴンアンタゴニスト及びglp−1アゴニスト活性を示す化合物
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
WO2009095479A2 (en) 2008-02-01 2009-08-06 Ascendis Pharma As Prodrug comprising a self-cleavable linker
EP2300037B1 (en) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
PL2300035T3 (pl) 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
MX2010012695A (es) 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
JP2012512898A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ジペプチド結合薬用剤
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체-활성 글루카곤 화합물
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
IN2012DN06437A (es) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
RU2604067C2 (ru) 2010-05-13 2016-12-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity

Also Published As

Publication number Publication date
TWI599575B (zh) 2017-09-21
KR20150023013A (ko) 2015-03-04
US9340600B2 (en) 2016-05-17
CN104583232B (zh) 2018-04-13
JP6311708B2 (ja) 2018-04-18
TW201402598A (zh) 2014-01-16
JP2015521622A (ja) 2015-07-30
CN104583232A (zh) 2015-04-29
CA2877358A1 (en) 2013-12-27
EP2864351A1 (en) 2015-04-29
RU2015101697A (ru) 2016-08-10
HK1209764A1 (en) 2016-04-08
ES2602486T3 (es) 2017-02-21
WO2013192129A1 (en) 2013-12-27
US20140011738A1 (en) 2014-01-09
EP2864351B1 (en) 2016-08-10
AR091477A1 (es) 2015-02-04

Similar Documents

Publication Publication Date Title
PH12014502857A1 (en) Analogs of glucagon exhibiting gip receptor activity
MX2014015558A (es) Analogos de glucagon que exhiben actividad del receptor gip.
MX2013006304A (es) Analogos de glucagon que exhiben actividad del receptor gip.
HRP20181678T1 (hr) Glukagon/glp-1 agonisti za liječenje pretilosti
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2016005560A (es) Compuestos agonistas triples de glucagon-glp-1-gip.
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
HK1202458A1 (en) Glucokinase activator compositions for the treatment of diabetes
GEP201706710B (en) Imidazopyridazine derivatives as gabaa receptor modulators
MX366636B (es) Nuevo derivado de un análogo de insulina.
MX2016008130A (es) Derivados de piperidina con actividad multimodal contra el dolor.
SG10201608485XA (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2015014470A (es) Analogos de combretastatina.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
NZ719451A (en) Glucagon analog for treatment of severe hypoglycemia
NZ719463A (en) Glucagon analog for treatment of severe hypoglycemia
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
TW201241006A (en) Glucagon analogs exhibiting GIP receptor activity
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
UA109404C2 (ru) 6-(2-r-метилселено)-2-оксо-4-фенил-3,5-дициано-1,2,3,4-тетрагидропиридины